Publications - Dr. Andrea Edginton

2025

  1. Hamadeh A*, Pellowe M*, Chelle P*, Yeung CHT*, Otalvaro J, Smith-Roberge J, Yamada W, Bartroff J, Kryshchenko A, Dallmann A, Solodenko J, Lippert J, Tsakalozou E, Neely M, Edginton AN. An open-source framework for virtual bioequivalence modeling and clinical trial design. CPT: Pharmacometrics & Systems Pharmacology. 2025. Accepted.
  2. Maglalang P, Sinha J, Etges Helfer V, Edginton AN, Zimmerman K, Hornik CD, Muller WJ, Rathore M, Benjamin DK, Chen J-Y, Anand R, Gonzalez D, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Physiologically-Based Pharmacokinetic Modeling of Oxcarbazepine to Characterize its Disposition in Children with Obesity. Journal of Clinical Pharmacology. 2025. Accepted.
  3. Kim M-S*, Hamadeh A, Kowalski J, Yeary A, Vij P, Torres J, Kim D, Edginton AN. A physiologically based kinetic model for quantifying human exposure to DEET. International Journal of Hygiene and Environmental Health. 2025; Jul:268 (114616). doi: 10.1016/j.ijheh.2025.114616.
  4. Hajducek D*, Sinkovic O, Chelle P*, Iorio A, Edginton AN. A global cross-sectional database study of low dose FVIII SHL prophylaxis in hemophilia A. Haemophilia. 2025; 31 (4), 646-656. doi:10.1111/hae.70061.
  5. McCann S, Helfer V, Balevic S, Muller W, van den Anker J, Al-Uzri A, Meyer M, Anderson S, Turdalieva S, Edginton AN, Gonzalez D. Physiologically-based and Population Pharmacokinetic Modeling of Midazolam in Children with Obesity Using Real-World Data. Clinical and Translational Science. 2025; 18(5): e60247. doi:10.1111/cts.70247.
  6. Hirniak S*, Edginton AN, Iorio A, Wong WWL. A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions. Pharmacoeconomics. 2025;43(7):765-778. doi:10.1007/s40273-025-01484-1
  7. Chelle P,* Hajducek D*, Iserman E, Iorio A, Edginton AN, the International Prophylaxis Study Group. Exploring the impact of laboratory reagents on pharmacokinetic profiling. Haemophilia. 2025; 0:1-9. doi: 10.1111/hae.70021.

2024

  1. Suryavanshi SV, Wang S*, Hajducek DM*, Hamadeh A*, Yeung CHT*, Maglalang PD, Ito S, Autmizguine J, Gonzalez D, Edginton AN. Coupling Pre- and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding. Clinical Pharmacokinetics. 2024; 63(12):1735-1748. doi: 10.1007/s40262-024-01447-3.  
  2. Najjar A, Hamadeh A, Krause S, Schepky A, Edginton AN. Global sensitivity analysis of Open Systems Pharmacology Suite physiologically based pharmacokinetic models. CPT: Pharmacometrics & Systems Pharmacology. 2024 13(8): 1394-1408. doi: 10.1002/psp4.13256
  3. Chelle P*, Hajducek D*, Thibaudeau K, Hobson N, Iorio A, Shapiro A, Edginton AN. Development of a Plasminogen Population PK model supporting prophylactic replacement therapy for Plasminogen deficient patients within the WAPPS-Hemo platform. Haemophilia. 2024; 30: 988–997. doi: 10.1111/hae.15027
  4. Keyvani F, Poudineh M, Soltani M, Zhao Y, Shakeri A, Chelle P*, Rahman F, Mahshid S, Quadrilatero J, Nekkar P, Edginton AN. Integrated Electrochemical Aptamer Biosensing and Colorimetric pH Monitoring via Hydrogel Microneedle Assays for Assessing Antibiotic Treatment. Advanced Science.  2024 11(41): e23-9027. doi: 10.1002/advs.202309027. 
  5. Kim M-S*, Hajducek D*, Gilbert J, Iorio A, Jilma B, Edginton AN. Kinetic modeling for BT200 to predict the level of plasma-derived coagulation factor VIII in humans. AAPS Journal. 26, 81 (2024). doi: 10.1208/s12248-024-00952-4
  6. Thompson E, Jeong A, Helfer V, Shakhnovich V, Edginton AN, Balevic S, James L, Collier D, Anand R, Gonzalez D, Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Physiologically-based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population. CPT: Pharmacometrics & Systems Pharmacology. 2024 13(8): 1394-1408. doi: 10.1002/psp4.13167
  7. Karatza E, Sinha J, Maglalang PD, Edginton A, Gonzalez D. Physiologically-Based Pharmacokinetic Modeling of Total and Unbound Valproic Acid to Evaluate Dosing in Children With and Without Hypoalbuminemia. Clinical Pharmacokinetics. 2024 63(10):1435-1448. doi: 10.1007/s40262-024-01418-8
  8. Maglalang PD, Sinha J, Zimmerman K, McCann S, Edginton A, Hornik CP, Hornik CD, Muller WJ, Al-Uzri A, Meyer M, Chen JY, Anand R, Perrin EM, Gonzalez D; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population. Clinical Pharmacokinetics. 2024 63(6)885-899. doi: 10.1007/s40262-024-01367-2
  9. Hajducek DM*, Chelle P*, Iorio A, Iserman E, Edginton AN. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo Hemophilia patients. Haemophilia. 2024;30 (4), 925-932. https://doi.org/10.1111/hae.15032
  10. Hirniak S*, Edginton AN, Iorio A, Alsabbagh MW, Hajducek DM, Wong WWL. Health utilities in adults with hemophilia A: A retrospective cohort study. Haemophilia. 2024;30(3):733-742. doi: 10.1111/hae.14979
  11. Hunt JP, Dubinsky S*, McKnite AM, Cheung KWK, van Groen B D, Giacomini K M, de Wildt SN, Edginton A N, & Watt K M. (2024). Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling. CPT: pharmacometrics & systems pharmacology, 13(4), 576–588. doi: 10.1002/psp4.13102
  12. Matino D, Germini F, Chan A, Decker K, Iserman E, Chelle P*, Edginton A, Oladoyinbo O*, Trinari E, Keepanasseril A, Iorio A. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with hemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. Haemophilia. 2024;30(2):345-354. doi:10.1111/hae.14960
  13. Yeung CHT*, Autmizguine J, Dalvi P, Denoncourt A, Lto S, Katz P, Rahman M, Theoret Y, Edginton AN. Maternal Ezetimibe Concentrations Measured in Breast Milk and its Use in Breastfeeding Infant Exposure Predictions. Clinical Pharmacokinetics. 2024; 63(3):3`7-332. doi: 10.1007/s40262-023-01345-0.
  14. Hamadeh A*, Nash JF, Bialk H, Styczynski P, Troutman J, Edginton A. Mechanistic skin modeling of plasma concentrations of sunscreen active ingredients following facial application. Journal of Pharmaceutical Sciences.2024 113(3): 806-825. doi: 10.1016/j.xphs.2023.09.017.